Harrow, Inc. reports results for the quarter ended June 30 - Earnings Summary
Harrow, Inc. reports results for the quarter ended June 30 - Earnings Summary
Harrow, Inc. HROW.OQ reported a quarterly adjusted loss of 46 cents per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of 13 cents. The mean expectation of eight analysts for the quarter was for a loss of 18 cents per share. Wall Street expected results to range from -50 cents to 1 cents per share.
Revenue rose 10.9% to $70.66 million from a year ago; analysts expected $70.34 million.
Harrow, Inc.'s reported EPS for the quarter was a loss of 46 cents.
The company reported a quarterly loss of $17.27 million.
Harrow, Inc. shares had fallen by 4.8% this quarter and lost 17.5% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had fallen by about 447.8% in the last three months.
In the last 30 days, two analysts negatively revised earnings estimates
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy"
Wall Street's median 12-month price target for Harrow, Inc. is $60.00, about 32.6% above its last closing price of $40.44
This summary was machine generated from LSEG data August 10 at 09:00 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
Jun. 30 2026 | -0.18 | -0.46 | Missed |
Mar. 31 2026 | -0.40 | -0.74 | Missed |
Dec. 31 2025 | 0.37 | 0.17 | Missed |
Sep. 30 2025 | 0.26 | 0.22 | Missed |
Recent news on Harrow
See all newsHarrow, Inc. reports results for the quarter ended June 30 - Earnings Summary
Harrow Q2 revenue slightly beats estimates
Viatris raises annual profit forecast on branded drug strength
Brief: Harrow Re-Launches Verkazia® (Cyclosporine Ophthalmic Emulsion) 0.1% For Vernal Keratoconjunctivitis, Addressing Significant Unmet Need In Pediatric Eyecare
Harrow Q1 revenue misses analyst estimates